Efficacy and Safety Data for CAR T Therapies in Marginal Zone Lymphoma

Panelists discuss how recent studies have demonstrated the potential of CAR T-cell therapy to provide meaningful benefit for patients with marginal zone lymphoma who have exhausted other options. Clinical evidence shows strong response rates and encouraging durability, highlighting CAR T’s potential as a transformative therapy for this patient population.

Safety findings mirror those in other B-cell lymphomas, with immune-related adverse effects that are largely manageable through careful monitoring and intervention. Clinical teams are gaining confidence in managing these reactions, allowing patients to receive treatment safely while minimizing discomfort.

The growing body of evidence positions CAR T therapy as a promising option for relapsed or refractory marginal zone lymphoma. Continued research and real-world experience will refine patient selection and maximize the potential for long-lasting remission.